NYSE:TEVAPharmaceuticals
Teva (TEVA) Is Up 8.8% After Raising 2026 Guidance And Highlighting Innovative Drug Momentum
Teva Pharmaceutical Industries’ recent second-quarter 2026 results showed relatively stable sales of US$4,142 million but a swing from profit to a net loss, alongside lower intangible asset impairments, while the company slightly raised its 2026 revenue guidance to US$16.50–US$16.85 billion and affirmed mid-single digit revenue growth targets for 2027.
The shift to direct NYSE listing of ordinary shares, coupled with the Emalex Biosciences acquisition and strong AUSTEDO, AJOVY, and UZEDY...